Huma powers digital-first research accelerating therapies for patients
Our award-winning technology supports decentralized and hybrid clinical trials that get effective treatments to patients faster. Our DCT platform can improve trial participation, diversity, engagement and efficiency, at scale.
Transforming research
3000+ hospitals and clinics supported across Huma platforms to secure the most sustainable impact for patients1
Our platform can almost double clinical capacity and reduce readmission rates by >30%2
Huma's digital-first health platforms support a network of 27m patients1
Over 1 million devices have been shipped in support of our projects and we know what it takes to deploy at scale1
Huma’s DCT platform capabilities
Powering some of the world’s largest DCTs, Huma enables better research by remotely collecting real-world data.
Our platform supports multiple participant recruitment strategies, including social media and marketing
Use questionnaires, videos and images to facilitate robust collection of research-grade clinical data via app or web
Access broader populations and identify suitable participants with remote screening, and onboard them using ID verification
Enabling capture of vital and non-vital signs through connected medical devices, sensors and wearables - with over 1m devices included to date
Seamlessly obtain informed consent with engaging and educational content that can build trust and support retention³
Provide tele-visit and tele-consent, messaging and clinical support through secure video and audio consultations, to make logistics and communication easier³
Increase inclusivity by allowing participants to add carers and proxies who can respond to study activities on their behalf
Engage and inform participants with educational content about the research study, how it will operate, ongoing support and relevant contact details
Manage multiple sites within a web-based portal, with data on target enrolment numbers, recruitment performance and study protocol compliance
Allows real-time visualisation of participant data, with built-in flagging systems to detect non-compliance or clinical events, to intervene as necessary
Smart analytics dashboards with deep and configurable permission layers for easy access to data for all relevant stakeholders
Sponsors and CROs can securely communicate with participants through messages, video and audio calls. Remote visits can be scheduled or participants can be contacted immediately³
Participant-generated data can be exported at any time from Huma's systems, in multiple file formats. The data can then be consumed onwards and refresh EDC systems and registries
Participants who do not have access to a smartphone can ring a call-centre, whose staff can use the web portal to answer questionnaires on their behalf
Manage multiple sites within a web-based portal, with data on target enrolment numbers, recruitment performance and study protocol compliance
Allows real-time visualisation of participant data, with built-in flagging systems to detect non-compliance or clinical events, to intervene as necessary
Smart analytics dashboards with deep and configurable permission layers for easy access to data for all relevant stakeholders
Sponsors and CROs can securely communicate with participants through messages, video and audio calls. Remote visits can be scheduled or participants can be contacted immediately³
Participant-generated data can be exported at any time from Huma's systems, in multiple file formats. The data can then be consumed onwards and refresh EDC systems and registries
Participants who do not have access to a smartphone can ring a call-centre, whose staff can use the web portal to answer questionnaires on their behalf
Benefits of the platform
How our DCT platform can help accelerate timelines and reduce costs
Faster decision-making with real-time analytics
Customise dashboards to provide real-time insights regarding site and participant performance, help proactively and safely monitor participants and improve protocol adherence
Keep participants engaged and
improve retention
Intuitive UI design, educational content and notifications to optimise participation and engagement, whilst seamless device connection and tele-visits reduce patient burden
Research-grade data collection
Collect robust, high-quality health data from sensors, devices and questionnaires with our comprehensive platform
Connect and combine
Flexible connection with Electronic Data Capture and other datasets / registries, as well as near real- time access to Electronic Health Records, pharmacy and claims records to build a richer patient profile4
Award-winning platform
Winner of the 2022 Prix Galien award for digital health, widely regarded as 'pharma's Nobel prize'9
Selected as one of 'The Most Important Healthcare Design of 2021' by Fast Company5
Global innovator, unicorn community
Selected as one of ‘Europe’s 1000 Fastest Growing Companies of 2023’ by Financial Times
Who we work with
Huma has deployments with top 10 pharmaceutical companies, national governments, major healthcare providers and leading research institutions around the world and was selected to power one of the largest global decentralised clinical trials for AstraZeneca
Our experience in delivering better research
Supporting AstraZeneca with an international Phase IV study
AstraZeneca selected our DCT platform to support one of the world’s largest decentralized clinical trials. Designed to use remote recruitment, ID verification, and safety data collection through our secure platform, the first patient was recruited less than three months after the project was signed. In order to ensure access for all populations, participants have multiple means to engage and are able to submit data on either an app, web portal or through a call centre.
Participants for target enrollment
Different countries and languages
Continents
Powering a DCT in atrial fibrillation with Bayer and Stanford Medicine
Huma, Bayer, Stanford Medicine and the Stanford Center for Digital Health together demonstrated the feasibility, for the first time, of a scalable, fully decentralized cardiovascular intervention trial requiring remote physiologic measurements among participants with atrial fibrillation. The trial had a robust recruitment strategy and strong engagement. Participants successfully transmitted physiologic BP and ECG measurements, tracked OAC adherence, completed regular surveys and televisits using Huma’s DCT platform. The findings provide a strong foundation to inform the design and conduct of future decentralized protocols for cardiovascular trials.
94% of participants recruited in 12 days6
Increased oral anticoagulation adherence from 85% to 96% in patients with low baseline6
Participant retention6
Pioneering a decentralized clinical study with the University of Cambridge
Huma partnered with the University of Cambridge (Medical Research Council Epidemiology Unit) to understand the progression of COVID-19 infection and build predictive models for pre-symptomatic infection. The study uses Huma’s digital platform to remotely collect data from nearly 2,500 participants from the Fenland cohort. This builds on 15 years worth of retrospective data to generate new insights and a joint analytics dataset for digital biomarker discovery.
Data points collected over 10 months7
Population-based app study of its kind7
Person days of data +3,500 historical metrics per participant7
Interventional Trial For High-Risk Type 2 Diabetes Patients
The study is a collaboration between Huma, Astra Zeneca and Imperial Health Partners. With the initial promising results from the interventional trial that included 600 participants, the aim is to scale the programme nationally, to create a real-world dataset to support high-quality research and transform care pathways for patients with type 2 diabetes, reducing complications and improving outcomes.
of participants improved their diets/average weight loss of 4.1kg8
Protocol compliance rate8
average reduction in HbA1c8
Regulatory, safety and compliance
MHRA registered Medical Device Class IIb
Part 11
Part 50
Part 820 ff
ISO 13485: 2016 certified (Medical Devices: Quality Management Systems)
ISO 27001: 2013 certified
Committed to GDPR compliance
NHS Registration on Data Security and Protection Toolkit
CyberEssentials / CyberEssentials Plus
Talk to us
Talk to us
Shanghai
Room 123, 13th Floor
Shanghai Tower
No. 501 Yincheng Middle Road
China
For all China enquiries
Munich
(DACH-Region)
Huma Therapeutics GmbH
Rundfunkplatz 2
80335 Munich
For all enquiries
